Contemporary immunomodulatory therapy for multiple sclerosis

Journal of Neuro-Ophthalmology

Volumn 21, Issue 4, 2001, Pages 284-291

  Rudick, R A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; MITOXANTRONE; RECOMBINANT INTERFERON;

CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MARKETING; DRUG STRUCTURE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT OUTCOME;

EID: 0035663473     PISSN: 10708022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041327-200112000-00012     Document Type: Conference Paper

References (41)

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
2. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
3. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis
4. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial
5. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
6. A phase III trial of intramuscular recombinant beta interferon as treatment of exacerbating-remitting multiple sclerosis: Design and conduct of study and baseline characteristics of patients
7. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
8. Interferon beta1b is effective in relapsing-remitting multiple sclerosis. II, MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
9. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrastenhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis
10. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis
11. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
12. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
13. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years
14. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis
15. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNβ-1a) for relapsing multiple sclerosis
16. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
17. Immunogenicity of interferon-beta in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration
18. Interferon beta in the treatment of multiple sclerosis. Mechanisms of action
19. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells
20. Interferon (IFN) beta acts downstream of IFN-gamma-induced class 11 transactivator messenger RNA accumulation to block major histocompatlbility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma
21. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis
22. Interferon -1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9
23. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b
24. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis
25. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis
26. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
27. Assessment of the efficacy of copolymer-1 in the treatment of multiple sclerosis by quantitative MRI
28. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: Quantitative MR assessment
29. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis
30. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging: Measured disease activity and burden in patients with relapsing multiple sclerosis
31. Placebo-controlled multicenter randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
32. Randomized controlled trial of interferon-beta-1a in secondary progressive MS Clinical results
33. Development of a multiple sclerosis functional composite as a clinical trial outcome measure
34. The Multiple Sclerosis Functional Composite Measure (MSFC): An integrated approach to MS clinical outcome assessment
35. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force
36. Induction of a nonencephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
37. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
38. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production
39. Self-determinants in autoimmune demyelinating disease: Changes in T-cell response specificity
40. Diversity and plasticity of self-recognition during the development of multiple sclerosis
41. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS